• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $TTNP

    Titan Pharmaceuticals Inc.

    Subscribe to $TTNP
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program, TP-2021 for use in combination with ProNeura technology for treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including non-clinical evaluation of the ProNeura platform in malaria prophylaxis. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.

    IPO Year:

    Exchange: NASDAQ

    Website: titanpharm.com

    Peers

    $AERI
    $CTXR
    $SPPI
    $TMDI

    Recent Analyst Ratings for Titan Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Titan Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock

    NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the "Purchase Agreement") with Blue Harbour Asset Management L.L.C-FZ ("Blue Harbour"), it has completed a private placement of the Company's newly designated Series C Convertible Preferred Stock (the "Preferred Stock"). Pursuant to the Purchase Agreement, Blue Harbour purchased 60,000 shares of Preferred Stock for an aggregate purchase price of $600,000. The shares have a conversion price of $3.40. The Certificate of Designations authorizing the Preferred Stock contains a beneficial ownership conversion "blocke

    6/27/25 4:05:00 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.

    NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") announced today the filing by Black Titan Corporation with the U.S. Securities and Exchange Commission ("SEC") of a registration statement on Form F-4 in connection with the proposed combination of Titan and TalenTec Sdn. Bhd. (f/k/a KE Sdn. Bhd.) ("TalenTec"), which includes Titan's preliminary proxy statement (the "Form F-4") As previously announced on August 19, 2024, Titan and TalenTec have entered into a Merger and Contribution and Share Exchange Agreement (the "Merger Agreement") regarding a business combination, pursuant to which Titan will be combined with TalenTec in a

    6/3/25 8:45:44 AM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock

    NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the "Purchase Agreement") with Blue Harbour Asset Management L.L.C-FZ ("Blue Harbour"), it has completed a private placement of the Company's newly designated Series B Convertible Preferred Stock (the "Preferred Stock"). Pursuant to the Purchase Agreement, Blue Harbour purchased 100,000 shares of Preferred Stock for an aggregate purchase price of $1,000,000. The shares have a conversion price of $3.00. The Certificate of Designations authorizing the Preferred Stock contains a beneficial ownership conversion "bl

    4/11/25 4:15:09 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

    NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan") today reported that it received a notice (the "5250 Notice") on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) ("Rule 5250") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the "Q3 Form 10-Q") in a timely manner. Under Nasdaq rules, the Company has 60 calendar days from receipt of the 5250 Notice or until January 21, 2025, to submit a plan to

    11/27/24 4:05:55 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.

    NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan") today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the "Merger Agreement") regarding a business combination with KE Sdn. Bhd. ("KE"). The Merger Agreement was approved by Titan's board of directors (the "Board"). If the Merger Agreement is approved by the stockholders of Titan and KE (and the other closing conditions are satisfied or waived in accordance with the Merger Agreement), and upon consummation of the transactions contemplated by the Merger Agreement (the "Closing"), Titan will be combined with KE in a "reverse merger" transaction consisting

    8/19/24 4:11:12 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria

    SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced that by letter dated January 24, 2024, the Company was notified by The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum $1.00 bid price requirement and otherwise satisfies all applicable criteria for continued listing on The Nasdaq Capital Market. As such, the listing matter has been closed.  About Titan Pharmaceuticals Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with utilizing ProNeura® long-term, conti

    1/25/24 4:29:23 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals Announces Reverse Stock Split and Ratio

    SOUTH SAN FRANCISCO, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's common stock, which will be effective following the filing of an amendment to the Company's Amended and Restated Certificate of Incorporation (the "Amendment"). The Company's stockholders approved the reverse stock split at a Special Meeting of Stockholders on December 27, 2023. The Company's shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market following the filing of the Amendment, which is intended go effective on January 9, 20

    12/28/23 4:15:00 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors

    SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") is pleased to announce the appointments of Dato' Seow Gim Shen and Brynner Chiam to the Company's Board of Directors, effective October 12, 2023. Mr. Shen has also been appointed Chairman of the Board. Simultaneous with the election of Mr. Shen and Mr. Chiam to the Board, David E. Lazar and Peter L. Chasey each submitted their resignations from the Board, effective immediately. These resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices. Mr. Lazar will remain with the Company as Chief Execut

    10/16/23 4:37:23 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock

    SAN FRANCISCO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") announced today that it has entered into a definitive securities purchase agreement (the "Purchase Agreement") with The Sire Group Ltd. ("Sire Group") for the sale of the Company's newly designated Series AA Convertible Preferred Stock (the "Preferred Stock"). Sire Group purchased 950,000 shares of Preferred Stock for an aggregate purchase price of $9,500,000, consisting of (i) $5 million in cash at closing and (ii) $4.5 million in the form of a promissory note from Sire Group, personally guaranteed by a principal of Sire Group, due and payable on September 23, 2023, subje

    9/18/23 7:30:00 AM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets

    SAN FRANCISCO, July 27, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced that it has entered into an Asset Purchase Agreement (the "Agreement") with Fedson, Inc., a Delaware Corporation ("Fedson"), for the sale of certain ProNeura assets including Titan's portfolio of drug addiction products, in addition to other early development programs based on the ProNeura drug delivery technology. The Company's addiction portfolio consists of the Probuphine and Nalmefene implant programs.  Under the terms of the Agreement, Fedson will purchase the ProNeura assets from Titan for an upfront purchase price of $2 million ($1 million at closing

    7/27/23 7:30:00 AM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Loh Gabriel claimed no ownership of stock in the company (SEC Form 3)

    3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

    5/5/25 1:50:21 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Jye Chay Weei claimed no ownership of stock in the company (SEC Form 3)

    3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

    4/16/25 3:49:51 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Mokhtar Firdauz claimed no ownership of stock in the company (SEC Form 3)

    3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

    4/5/24 10:14:05 AM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Flores Francisco claimed no ownership of stock in the company (SEC Form 3)

    3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

    4/5/24 10:13:26 AM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Choong Choon Hau converted options into 54,132 shares, increasing direct ownership by 1% to 3,802,100 units (SEC Form 4)

    4 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

    3/27/24 9:45:40 AM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Chiam Brynner claimed no ownership of stock in the company (SEC Form 3)

    3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

    10/23/23 3:07:26 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Sire Group Ltd. claimed ownership of 20,836,266 shares (SEC Form 3)

    3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

    10/4/23 4:40:50 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4: Greenberg Eric Howard was granted 50,000 shares

    4 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

    7/31/23 8:06:23 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4: Natan David was granted 50,000 shares (Amendment)

    4/A - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

    7/31/23 7:45:55 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4: Chasey Peter Louis was granted 50,000 shares (Amendment)

    4/A - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

    7/31/23 7:44:17 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Titan Pharmaceuticals upgraded by Maxim Group with a new price target

    Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy and set a new price target of $11.00

    2/25/21 10:45:32 AM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals upgraded by Maxim Group

    Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy

    2/18/21 8:31:20 AM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals upgraded by Maxim Group with a new price target

    Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy and set a new price target of $11.00

    2/18/21 7:31:23 AM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals Inc. SEC Filings

    View All

    SEC Form DEFA14A filed by Titan Pharmaceuticals Inc.

    DEFA14A - TITAN PHARMACEUTICALS INC (0000910267) (Filer)

    8/14/25 5:16:04 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Titan Pharmaceuticals Inc.

    10-Q - TITAN PHARMACEUTICALS INC (0000910267) (Filer)

    8/14/25 4:07:46 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Titan Pharmaceuticals Inc.

    DEFA14A - TITAN PHARMACEUTICALS INC (0000910267) (Filer)

    7/22/25 5:06:53 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFM14A filed by Titan Pharmaceuticals Inc.

    DEFM14A - TITAN PHARMACEUTICALS INC (0000910267) (Filer)

    7/22/25 5:04:26 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - TITAN PHARMACEUTICALS INC (0000910267) (Filer)

    6/27/25 4:15:19 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - TITAN PHARMACEUTICALS INC (0000910267) (Filer)

    6/18/25 4:49:02 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 425 filed by Titan Pharmaceuticals Inc.

    425 - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

    6/3/25 5:25:48 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - TITAN PHARMACEUTICALS INC (0000910267) (Filer)

    6/3/25 5:25:13 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - TITAN PHARMACEUTICALS INC (0000910267) (Filer)

    6/2/25 5:20:12 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Titan Pharmaceuticals Inc.

    10-Q - TITAN PHARMACEUTICALS INC (0000910267) (Filer)

    5/14/25 4:05:26 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Titan Pharmaceuticals Inc.

    SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

    8/21/24 8:32:38 AM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Titan Pharmaceuticals Inc. (Amendment)

    SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

    4/5/24 4:34:04 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Titan Pharmaceuticals Inc.

    SC 13D - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

    10/4/23 5:30:18 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Titan Pharmaceuticals Inc.

    SC 13D - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

    7/20/23 9:57:45 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Titan Pharmaceuticals Inc. (Amendment)

    SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

    6/23/23 4:05:16 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Titan Pharmaceuticals Inc. (Amendment)

    SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

    12/15/22 8:10:36 AM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Titan Pharmaceuticals Inc. (Amendment)

    SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

    8/17/22 4:00:16 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Titan Pharmaceuticals Inc. (Amendment)

    SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

    7/8/22 10:38:56 AM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Titan Pharmaceuticals Inc. (Amendment)

    SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

    6/9/22 2:38:42 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Titan Pharmaceuticals Inc.

    SC 13D - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

    4/25/22 2:55:09 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    View All

    Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

    NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan") today reported that it received a notice (the "5250 Notice") on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) ("Rule 5250") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the "Q3 Form 10-Q") in a timely manner. Under Nasdaq rules, the Company has 60 calendar days from receipt of the 5250 Notice or until January 21, 2025, to submit a plan to

    11/27/24 4:05:55 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors

    SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") is pleased to announce the appointments of Dato' Seow Gim Shen and Brynner Chiam to the Company's Board of Directors, effective October 12, 2023. Mr. Shen has also been appointed Chairman of the Board. Simultaneous with the election of Mr. Shen and Mr. Chiam to the Board, David E. Lazar and Peter L. Chasey each submitted their resignations from the Board, effective immediately. These resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices. Mr. Lazar will remain with the Company as Chief Execut

    10/16/23 4:37:23 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care